Table 1.

Infliximab Use in Patients with Intestinal Behçet’s Disease

Author (year)	Country	Method	Participants	Intervention	Outcomes
Iwata et al. (2011)24	Japan	Retrospective, 1 center	10 Patients with intestinal BD refractory to conventional therapy	IFX 3–5 mg/kg (wk 0, 2, 6) with methotrexate	Primary outcome Rate of disappearance of ileocecal ulceration at 6 and 24 mo: 50% and 90% Secondary outcome Dose of steroid tapered at 24 mo: 22.0–1.8 mg/day
Lee et al. (2013)25	Korea	Retrospective, 8 centers	28 Patients with moderate to severe activity of intestinal BD (DAIBD ≥40)	IFX 5 mg/kg (wk 0, 2, 6)	Primary outcome Clinical remission at 2, 4, 30, and 54 wk (DAIBD <20): 32.1%, 28.6%, 46.2%, and 39.1% Secondary outcome Clinical response at 2, 4, 30, and 54 wk (ΔDAIBD ≥20): 75%, 64.3%, 50%, and 39.1% Biological response at 2, 4, 30, and 54 wk (CRP <3 mg/L): 82.1%, 57.1%, 53.8%, and 43.5%
Kinoshita et al. (2013)26	Japan	Retrospective, 1 center	15 Patients with refractory intestinal BD to conventional therapy	IFX 5 mg/kg (wk 0, 2, 6) (n=10) IFX 5 mg/kg (wk 0, 2, 6) with azathioprine (n=5)	Primary outcome Clinical remission at 10 wk, 12 mo, and 24 mo (improved symptom and normal CRP): 53%, 27%, and 38% Secondary outcome Clinical response at 10 wk, 12 mo, and 24 mo (improved symptom or lower CRP): 27%, 36%, and 38%
Ideguchi et al. (2014)27	Japan	Retrospective, 1 center	43 (6 Treated with infliximab for intestinal BD) patients with intestinal BD to conventional therapy	-	Good response in 2 patients, partial response in 2, and unchanged GI lesions in 2 patients
Vallet et al. (2015)28	France	Retrospective, 12 centers	124 (9 Treated with infliximab for intestinal BD)	-	Primary outcome Complete response: 5/9 (55.6%) Secondary outcome Improvement of clinical manifestations in BD patients treated by infliximab: 7/9 (77.8%)
Hibi et al. (2016)29	Japan	Prospective, open-label, single-arm phase 3 study, 21 centers	18 (11 With intestinal BD) patients with refractory intestinal BD to conventional therapy	IFX 5 mg/kg (wk 0, 2, 6)	Primary outcome Complete responder at 14, 30, and 54 wk (disappeared clinical symptom and healed or scarred ulcer): 55%, 55%, and 60% Secondary outcome Dose reduction and withdrawal of steroids at 14, 30, 54 wk: 37.5%, 75.0%, and 100.0%
Zou et al. (2017)30	China	Retrospective, 1 center	27 Patients with moderate to severe activity of intestinal BD (DAIBD ≥40)	-	Primary outcome Clinical remission at 14, 30, and 52 wk (DAIBD <20): 69.2%, 40%, and 55% Secondary outcome Clinical response at 14, 30, and 52 wk (ΔDAIBD ≥20): 84.6%, 70%, and 70% Mucosal healing at 14 wk: 72%

BD, Behçet’s disease; IFX, infliximab; DAIBD, disease activity score for intestinal BD; CRP, C-reactive protein; GI, gastrointestinal.